Check how their findings suggest that P4HB could serve not only as a potential therapeutic target for glioblastoma but also as a biomarker for auxiliary diagnosis and monitoring of disease progression.

Check how PANX1 triggers rhabdomyosarcoma cell fusion by downregulating APOBEC2 expression, forcing these undifferentiated malignant cells further into the myogenic pathway, offering therapeutic potential by limiting malignant progression.

Check how this study provides novel mechanistic insights into the role of LUBAC in regulating HIF1α homeostasis, tumor angiogenesis and tumorigenesis of lung cancer, making LUBAC an attractive therapeutic target for cancers.

Check how this study uncovers a novel key pathway that drives renal cell carcinoma invasion and metastasis, offering a promising therapeutic target for clinical intervention.

Check how this study demonstrates that targeting KAT2A with a PROTAC degrader decreases MYCN activity and inhibits NB cell proliferation, which hold the potential to make a significant impact on the management of this aggressive childhood cancer.

Check how their findings reveal that targeting NFATc1 simultaneously restricts biosynthetic precursors and impairs cell cycle progression in CRC, suggesting that NFATc1 inhibition is a promising therapeutic strategy.

Check how this study unveils the involvement of the EPHA5-STAT3 signaling pathway in Follicular Thyroid Cancer and how this discovery offers a promising new target for genetic intervention in the its treatment.

Check how this study highlights LINC01432 as a potential therapeutic target for overcoming resistance in high-risk multiple myeloma.

Check how this study demonstrates that SYT7 functions as an oncoprotein in NPC, driving tumor progression through its regulation of ALDH1A3-mediated glycolysis and STAT3 signaling pathways, revealing its potential as a biomarker for the prediction and treatment of NPC.

Special thanks to the Scientific Committee:
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.

📢 Coming soon: Oncogenesis will publish a meeting report and launch a Special Issue on Metabolism and Cancer, featuring insights from 13 leading experts. Stay tuned! 👀

Romain RISCAL (IRCM - Institut de Recherche en Cancérologie de Montpellier) et Eric Solary (Gustave Roussy, Vice‑président de la Fondation ARC pour la recherche sur le cancer).

Jacqueline Lehmann-Che (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Paris), Camille Lobry (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Thomas Mercher ( @gustaveroussy.fr
Research, Villejuif), Julie Pannequin (Institut de Génomique Fonctionnelle - IGF, Montpellier)